Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Adding cediranib to chemo improves PFS for metastatic cervical cancer

Rare cancers and the difficulties in making clinical decisions

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Second-line afatinib significantly improves PFS in metastatic head and neck cancer

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Current treatment options in mRCC

Additional treatment options impact first-line treatment of mRCC: No

Additional treatment options impact first-line treatment of mRCC: Yes

Discussion: Additional treatment options impact first-line treatment of mRCC

From clinical trial to clinical practice: Evidence from the real world

What have we learned? Expert perspectives